We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

39 hedge funds and large institutions have $1.71M invested in SAB Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

3% more funds holding

Funds holding: 38 → 39 (+1)

0.18% less ownership

Funds ownership: 0.95% → 0.77% (-0.18%)

29% less capital invested

Capital invested by funds: $2.42M → $1.71M (-$706K)

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
39
Holders Change
+1
Holders Change %
+2.63%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
First Manhattan
First Manhattan
New York
+$176K
2
VF
Virtu Financial
New York
+$9.49K
3
TSS
Two Sigma Securities
New York
+$8.5K
4
TRCT
Tower Research Capital (TRC)
New York
+$2.94K
5
GI
GS Investments
Minnesota
+$1.26K

Top Sellers

Rank Fund Capital Flow
1
SCM
Shaolin Capital Management
Florida
-$140K
2
WAM
Warberg Asset Management
Illinois
-$122K
3
Citadel Advisors
Citadel Advisors
Florida
-$51.1K
4
AWM
AE Wealth Management
Kansas
-$11K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$6.75K
Name Holding Trade Value Shares
Change 		Change in
Stake
NFG
26
Nadler Financial Group
Illinois
$6.05K – – –
TSS
27
Two Sigma Securities
New York
$5.91K +$8.5K +1,344 New
KAS
28
Kestra Advisory Services
Texas
$4.84K – – –
1SB
29
1ST Source Bank
Indiana
$4.4K – – –
Baird Financial Group
30
Baird Financial Group
Wisconsin
$4.4K – – –
ECM
31
Elgethun Capital Management
South Dakota
$3.22K -$4.91K -776 -52%
UBS Group
32
UBS Group
Switzerland
$2.94K -$158 -25 -4%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$2K – – –
GI
34
GS Investments
Minnesota
$880 +$1.26K +200 New
HI
35
Harbour Investments
Wisconsin
$220 +$316 +50 New
Wells Fargo
36
Wells Fargo
California
$82 – – –
NA
37
NewEdge Advisors
Louisiana
$64 – – –
Barclays
38
Barclays
United Kingdom
$24 +$32 +5 New
SCM
39
Shaolin Capital Management
Florida
– -$140K -23,662 Closed
AWM
40
AE Wealth Management
Kansas
– -$11K -1,870 Closed
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
– -$6.75K -1,144 Closed
MCC
42
Money Concepts Capital
Florida
– -$147 -25 Closed
Bank of America
43
Bank of America
North Carolina
– -$22 -4 Closed
1
2

SABS Hedge Fund Activity: Q1 2023 in Review

39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2023, worth a combined $1.71M — down 29% from $2.42M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new SABS positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 7 trimmed.

The largest buyer was First Manhattan, opening a new position worth an estimated $176K. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $140K sold.

  • 39 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2023, up from 38 in Q4 2022.
  • Funds reported $1.71M of SAB Biotherapeutics stock for Q1 2023, down 29% quarter-over-quarter.
  • 7 funds opened new SAB Biotherapeutics positions in Q1 2023 and 6 closed out, a net change of +1 holder.
  • The largest SAB Biotherapeutics buyer in Q1 2023 was First Manhattan, an estimated $176K added.
  • The largest SAB Biotherapeutics seller in Q1 2023 was Shaolin Capital Management, an estimated $140K sold.

Based on aggregated 13F filings for Q1 2023.